Drug–polymer solid dispersion has been demonstrated as a feasible approach to formulate
poorly water-soluble drugs in the amorphous form, for the enhancement of dissolution rate …

Since the past several decades, poor water solubility of existing and new drugs in the
pipeline have remained a challenging issue for the pharmaceutical industry. Literature …

The number of active pharmaceutical substances having high therapeutic potential but low
water solubility is constantly increasing, making it difficult to formulate these compounds as …

Amorphous solid dispersions containing a polymeric component often impart improved
stability against crystallization for a small molecule relative to the pure amorphous form …

The importance of amorphous pharmaceutical solids lies in their useful properties, common
occurrence, and physicochemical instability relative to corresponding crystals. Some …

The amorphous solid state offers an improved apparent solubility and dissolution rate.
However, due to thermodynamic instability and recrystallization tendencies during …

The characterization and performance of stable amorphous solid dispersion systems were
evaluated in 40 research papers reporting active pharmaceutical ingredient (API) dissolution …

Dissolution of amorphous solid dispersions (ASD) can lead to the formation of amorphous
drug-rich nano species (nanodroplets) via liquid–liquid phase separation or glass–liquid …

Amorphous solid dispersion formulations (ASD) are increasingly being used as a
formulation strategy to improve bioavailability of poorly soluble drugs. One of the limitations …

Solubility is one of the major problems associated with most of the new chemical entities that
can be reasonably addressed by drug amorphization. However, being a high-energy form, it …